Introduction
============

Evidence-based guidelines recommend long-term use of low-dose acetylsalicylic acid (ASA; 75--150 mg/day) for all patients with ischemic cardiovascular disease, unless contraindicated (Sacco et al., [@B25]; Smith et al., [@B26]; King et al., [@B15]). Low-dose ASA is known to be effective for the prevention of cardiovascular events in high-risk patients, reducing the risk of serious vascular events by around 25% (Antithrombotic Trialists' Collaboration, [@B1]). However, low-dose ASA is also known to increase the risk of upper gastrointestinal bleeding (UGIB) (Lanas et al., [@B17]). Numerous observational studies have shown that the risk of upper gastrointestinal complications in patients receiving low-dose ASA is around twofold that in the general population (Weil et al., [@B28]; de Abajo and García Rodríguez, [@B5]; García Rodríguez et al., [@B9]).

Therefore, the cardiovascular benefits of low-dose ASA therapy should be weighed against the risk of any major bleeding, including UGIB. Risk factors for UGIB in patients taking ASA are not well characterized, but appear to include advanced age, history of peptic ulcer disease and concomitant use of NSAIDs (Patrono et al., [@B24]). A dose of ASA not greater than 81 mg per day together with a gastroprotective medication is recommended for patients at high risk of bleeding (Bhatt et al., [@B2]).

The aims of this study were to estimate the incidence of UGIB in a UK primary care setting and, through a nested case--control analysis, establish the principal risk factors associated with an increased risk of UGIB among a cohort of individuals starting low-dose ASA therapy for secondary prevention of cardiovascular events.

Materials and Methods
=====================

Data source
-----------

The Health Improvement Network (THIN) covers about 5% of the UK population, and is age, sex, and geographically representative (Bourke et al., [@B3]). Anonymized data on over 3 million patients are systematically recorded by participating primary care practitioners (PCPs) as part of their routine patient care and sent to THIN for use in research projects. The computerized information includes demographics, details from PCP visits, diagnoses, referrals to specialists and hospital admissions, results of laboratory tests, and a free-text section. Participating practices are required to record the indication for new courses of therapy, and prescriptions issued by the PCP are also recorded. The Read classification is used to code specific diagnoses (O\'Neil et al., [@B23]; Stuart-Buttle et al., [@B27]), and a drug dictionary based on data from the MULTILEX classification is used to record prescriptions (First Data Bank, [@B6]). THIN has been extensively validated for use in pharmacoepidemiology (Lewis et al., [@B20]).

Study design
------------

From THIN, a cohort of new users of low-dose ASA (75--300 mg/day) for secondary prevention of cardiovascular ischemic diseases or cerebrovascular ischemic events who were aged 50--84 years between 1 January 2000 and 31 December 2007 was sampled. They were required to be registered for at least 2 years with their PCP and to have at least 1 year of computerized prescription history. We excluded all individuals with any of the following conditions: alcohol abuse, cancer, coagulopathies, esophageal varices, liver disease or Mallory--Weiss disease. The date of the first ever recorded prescription of low-dose ASA for secondary prevention of cardiovascular or cerebrovascular events was defined as the start date. All study cohort members (*N* = 38 077) were followed for a mean of 4.0 years from the first day after the start date until the earliest of the following endpoints: UGIB event; diagnosis of alcohol abuse/alcohol-related disease, cancer, coagulopathy, esophageal varices, liver disease, or Mallory--Weiss disease; reaching the age of 85 years; death or the end of the study period (30 October 2008). The study was approved by a Multicentre Research Ethics Committee.

UGIB case ascertainment
-----------------------

After removing all personal identifiers, we reviewed the free-text comments and patient profiles which included demographic data and all clinical information for all individuals with a computer-recorded entry suggesting a UGIB event (*n* = 548). At this stage, patients were excluded if they had bleeding in a location other than the stomach or duodenum, or if they had no specific bleeding site recorded (unless it was recorded as "peptic ulcer"). Individuals were also excluded if they had gastrointestinal perforation, if the UGIB event was not confirmed upon further investigation or if they were not referred, or if they had a diagnosis of alcohol abuse/alcohol-related disease, cancer, coagulopathy, esophageal varices, liver disease, or Mallory--Weiss disease. During the manual review, we also established the index date as the day of the first sign (e.g. bleeding) that led to the diagnosed outcome.

Following this review process, 169 patients were considered to be incident cases of UGIB (Figure [1](#F1){ref-type="fig"}). The site of bleeding was located in the stomach in 71 (42%) patients, in the duodenum for 50 (29.6%), in both sites for 27 (16.0%), and in 21 (12.4%) patients the specific site was only recorded as "peptic ulcer".

![**Study design and case ascertainment**. UGIB, upper gastrointestinal bleeding.](fphar-01-00126-g001){#F1}

Selection of controls
---------------------

A date within the study period was generated at random for each member of the study cohort of 38 077 individuals. If the random date was included in the individual\'s eligible person-time (follow-up period), we marked that person as an eligible control. The random date for controls was used as the index date in the nested case--control analysis. In total, 2000 controls, frequency-matched by sex, age, and follow-up time (interval between start date and index date), were sampled. The same exclusion criteria were applied to controls as to cases.

Comorbidities and risk factors
------------------------------

Information on comorbidities was collected from THIN from any time before the start date. Peptic ulcer antecedents was categorized into three groups:*dyspepsia* which included all diagnoses related with upper gastrointestinal symptoms; *uncomplicated peptic ulcer*; and *complicated peptic ulcer* defined as all individuals with bleeding or another complication. Data on potential risk factors, such as smoking, alcohol use (units per week), body mass index (BMI; kg/m^2^) were collected from any time before the index date. In addition, data on the number of PCP visits, referrals and hospitalizations were collected for the year prior to the index date. Finally, information on drug exposure between the start date and the index date was reviewed.

Exposure to antiplatelet drugs (ASA, clopidogrel and dipyridamole), warfarin, nitrates, proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H~2~RAs), oral steroids was classified as follows: *current use*, when the supply of the most recent prescription lasted until the index date or ended in the 30 days before the index date; *past use*, when supply of the most recent prescription ended 31--365 days before the index date; and *non-use* when supply of the most recent prescription ended more than 365 days before the index date or there was no recorded use at any time between the start and index dates if that interval was smaller than 365 days. Additionally we evaluated the interaction between dual antiplatelet use (ASA + clopidogrel) and between ASA + NSAIDs, independently. We created five levels of exposure for each of these two variables as follows: *Non-use of either agent* (within the year prior to index date); *use of both agents* defined as current users of the two agents; *current use of only one agent and non-use of the other agent within the year prior*and vice versa; and *remaining* (combinations of recency of both agents).

To estimate the effect of low-dose ASA discontinuation on the risk of UGIB, we categorized ASA exposure using the following time windows: *current use*, when the supply of the most recent prescription lasted until the index date (assuming complete adherence) or ended in the 14 days before the index date; *recent discontinuation* when it ended 15--180 days before the index date; *past discontinuation* when it ended 181--365 days before the index date; and *non-use* when it ended more than 365 days before the index date. We also examined the reasons for low-dose ASA discontinuation and classified them into four mutually exclusive groups: *lack of efficacy*, defined as physician-initiated switching from low-dose ASA to another antiplatelet drug or to an anticoagulant such as warfarin with no evidence to suggest an adverse event; *safety concerns*, defined as evidence of adverse events related to low-dose ASA therapy (such as upper gastrointestinal disorders or UGIB), evidence of intolerance to low-dose ASA (allergy/urticaria), initiation of acid-suppressing drug treatment, or planned surgery; *use of over-the-counter ASA*, defined as when the PCP recorded that patients were receiving low-dose ASA in the absence of a computerized prescription or when the PCP noted that the patient was taking over-the-counter low-dose ASA; and *non-adherence*, defined as discontinuation in the absence of any of the above factors.

We subdivided current users of PPIs and H~2~RAs into two mutually exclusive groups: those who received their first prescription before or at the start date (defined as users initiating therapy at start date) and those who received their first prescription after the start date (defined as users initiating therapy after start date).

Exposure to NSAIDs was classified as follows: *current use*, when the supply of the most recent prescription lasted until the index date or ended in the 7 days before the index date (this shorter time window for NSAID current use was used to make it comparable with prior NSAID studies); *past use*, when it ended 8--365 days before the index date; and *non-use* when use ended more than 365 days before the index date or there was no recorded use at any time between the start and index dates if that interval was smaller than 365 days. Current use of NSAIDs was further subdivided into the following categories: *single*, when there was use of only one NSAID in the 90 days before the index date, and *multiple*, when the patient used more than one NSAID in the 90 days before the index date. Dose-- and duration--response were assessed in current users of single NSAIDs. Duration of treatment was computed by summing the number of days corresponding to consecutive prescriptions (allowing for an interval of 60 days or less between the end of one prescription and the start of the next one).

Statistical analysis
--------------------

The overall incidence of UGIB was estimated along with age- and sex-specific incidence estimates, and 95% confidence intervals (CIs) were calculated. We also calculated the incidence of UGIB in subgroups of ASA users with or without a history of peptic ulcer disease before the start date. Kaplan--Meier survival analysis and log rank test was performed in the whole cohort as well as stratified by sex, age, and history of peptic ulcer disease.

Nested case--control analysis was performed to estimate the association between various risk factors and the occurrence of UGIB. Odds ratios (ORs) and 95% CIs were calculated by unconditional multiple logistic regression models adjusted for age, sex, follow-up time, history of peptic ulcer disease, PCP visits, number of referrals and hospitalizations, and use of ASA, clopidogrel, warfarin, PPIs and NSAIDs (current, past, or no use). Under the study design of incidence density sampling, the OR is an unbiased estimator of the incidence rate ratio (RR). Statistical analyses were performed using Stata package version 11.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Incidence of UGIB
-----------------

We observed a crude incidence of UGIB of 1.12 per 1000 person-years (95% CI, 0.96--1.30). The incidence of UGIB increased with age and was slightly higher among men 1.18 (95% CI, 0.97--1.43) than women 1.05 (95% CI, 0.83--1.33) (Figure [2](#F2){ref-type="fig"}). There was no significant association between UGIB and sex (log rank test *p*value = 0.44), but older age was associated with UGIB (\>70 years vs ≤70 years; log rank test *p*value = 0.0003).

![**Incidence of UGIB by age and sex in a cohort of low-dose ASA users**. ASA, acetylsalicylic acid; UGIB, upper gastrointestinal bleeding.](fphar-01-00126-g002){#F2}

The incidence of UGIB was 3.53 per 1000 person-years (95% CI, 2.53--4.92) among individuals with a previous diagnosis of peptic ulcer disease, 1.44 per 1000 person-years (95% CI, 1.09--1.92) among individuals with a previous diagnosis of gastritis or dyspepsia, compared with 0.80 per 1000 person-years (95% CI, 0.65--0.99) among individuals with none of these diagnoses.

The cumulative proportion of patients developing UGIB over time is presented in Figure [3](#F3){ref-type="fig"}. The incidence during the first year of follow-up was 1.71 (95% CI, 1.34--2.20) per 1000 person-years and 0.93 (95% CI, 0.77--1.13) per 1000 person-years during the remaining years of follow-up. Figures [4](#F4){ref-type="fig"}--[6](#F6){ref-type="fig"} present the cumulative proportion of patients developing UGIB according to sex, age, and history of peptic ulcer disease, respectively.

![**Cumulative proportion of patients developing UGIB during follow-up**. UGIB, upper gastrointestinal bleeding.](fphar-01-00126-g003){#F3}

![**Cumulative proportion of patients developing UGIB, stratified by sex**. UGIB, upper gastrointestinal bleeding.](fphar-01-00126-g004){#F4}

![**Cumulative proportion of patients developing UGIB, stratified by age at start date**. UGIB, upper gastrointestinal bleeding.](fphar-01-00126-g005){#F5}

![**Cumulative proportion of patients developing UGIB, stratified by history of peptic ulcer disease or gastritis/dyspepsia**. UGIB, upper gastrointestinal bleeding.](fphar-01-00126-g006){#F6}

Risk factors for UGIB
---------------------

Associations between baseline characteristics and comorbidities and the risk of UGIB are shown in Table [1](#T1){ref-type="table"}. Consumption of more than 25 units of alcohol per week was associated with a significant increase in the risk of UGIB (RR, 2.96; 95% CI, 1.43--6.15; compared with non-use). The corresponding estimate of RR among current smokers was 1.33 (95% CI, 0.80--2.21 compared with non-smokers. Prior diagnosis of peptic ulcer disease (with or without complication) was also associated with a significant increase in the risk of UGIB (RR, 4.59; 95% CI, 2.87--7.33).

###### 

**The prevalence of demographic and lifestyle characteristics in individuals with UGIB and controls with no UGIB, and their association with a diagnosis of UGIB, in a cohort of low-dose ASA users**.

                                            Controls *N* = 2000   UGIB cases *N* = 169   RR (95% CI)\*          
  ----------------------------------------- --------------------- ---------------------- --------------- ------ --------------------
  **SEX**                                                                                                       
  Male                                      1189                  59.5                   101             59.8   NA
  Female                                    811                   40.6                   68              40.2   NA
  **AGE (YEARS)**                                                                                               
  \<65                                      468                   23.4                   38              22.5   NA
  65--74                                    670                   33.5                   58              34.3   NA
  ≥75                                       862                   43.1                   73              43.2   NA
  **FOLLOW-UP TIME (MONTHS)**                                                                                   
  0--6                                      439                   21.9                   39              23.1   NA
  7--12                                     257                   12.8                   23              13.6   NA
  12--23                                    428                   21.4                   35              20.7   NA
  24--47                                    484                   24.2                   41              24.3   NA
  ≥48                                       392                   19.6                   31              18.3   NA
  **SMOKING STATUS**                                                                                            
  Never                                     878                   43.9                   59              34.9   1 (--)
  Current                                   276                   13.8                   28              16.6   1.33 (0.80--2.21)
  Former                                    803                   40.2                   75              44.4   1.18 (0.81--1.73)
  Unknown                                   43                    2.1                    7               4.1    2.67 (1.08--6.59)
  **ALCOHOL USE (UNITS/WEEK)**                                                                                  
  0                                         903                   45.1                   68              40.2   1 (--)
  1--2                                      262                   13.1                   26              15.4   1.49 (0.91--2.44)
  3--24                                     599                   29.9                   46              27.2   1.11 (0.73--1.70)
  ≥25                                       72                    3.6                    12              7.1    2.96 (1.43--6.15)
  Unknown                                   164                   8.2                    17              10.1   1.52 (0.84--2.76)
  **HOSPITALIZATIONS**                                                                                          
  None                                      1616                  80.8                   112             66.3   1 (--)
  1--2                                      300                   15.0                   43              25.4   1.88 (1.24--2.86)
  ≥3                                        84                    4.2                    14              8.3    1.56 (0.79--3.05)
  **HISTORY OF GASTROINTESTINAL DISEASE**                                                                       
  None                                      1414                  70.7                   86              50.9   1 (--)
  Dyspepsia                                 450                   22.5                   49              29.0   1.77 (1.20--2.61)
  Peptic ulcer disease                      136                   6.8                    34              20.1   4.59 (2.87--7.33)
     Uncomplicated                          99                    5.0                    22              13.0   4.18 (2.44--7.15)
     Complicated                            37                    1.8                    12              7.1    5.73 (2.73--12.02)

\**Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, NSAIDs and PPIs*.

*Note: PCP visits, number of referrals and number of hospitalizations were collected for the year prior to the index date. A unit per alcohol: 1 unit = 10 ml of pure ethanol( 8 g of alcohol). Uncomplicated ulcer diseases: peptic ulcer without complication; complicated ulcer diseases: peptic ulcer with bleeding or perforation*.

*ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal anti-inflammatory drug; PCP, primary care practitioner; PPI, proton pump inhibitor; PU, peptic ulcer; RR, relative risk; UGIB, upper gastrointestinal bleeding*.

The RR of UGIB associated with current use of low-dose ASA was 1.63 (95% CI, 0.85--3.13) (Table [2](#T2){ref-type="table"}). The risk of UGIB was significantly increased in those receiving ASA 150--300 mg/day (RR, 2.65; 95% CI, 1.17--5.97). The corresponding RR among those receiving 75 mg/day was 1.54 (95% CI, 0.80--2.97).

###### 

**Medication use in individuals with UGIB and controls with no UGIB, and their association with a diagnosis of UGIB, in a cohort of low-dose ASA users**.

                                     Controls *N* = 2000   Cases *N* = 169   RR (95% CI)\*           
  ---------------------------------- --------------------- ----------------- --------------- ------- -----------------------------------
  **LOW-DOSE ASA**                                                                                   
  Non-use                            186                   9.3               13              7.7     1 (--)
  Current use (0--30 days)           1570                  78.5              136             80.5    1.63 (0.85--3.13)
     75 mg/day                       1425                  71.2              118             69.8    1.54 (0.80--2.97)
     150--300 mg/day                 145                   7.2               18              10.7    2.65 (1.17--5.97)
  Past use (31--365 days)            244                   12.2              20              11.8    1.31 (0.59--2.88)
  **CLOPIDOGREL**                                                                                    
  Non-use                            1813                  90.6              139             82.2    1 (--)
  Current use (0--30 days)           149                   7.4               22              13.0    1.90 (1.12--3.22)
  Past use (31--365 days)            38                    1.9               8               4.7     2.40 (1.04--5.55)
  **INTERACTION WITH CLOPIDOGREL**                                                                   
  Low-dose ASA with                  1439                  72.0              114             67.5    1 (--)no clopidogrel
  Low-dose ASA                       103                   5.2               14              8.3     1.61 (0.85--3.05)plus clopidogrel
  **WARFARIN**                                                                                       
  Non-use                            1907                  95.3              161             95.3    1 (--)
  Current use (0--30 days)           75                    3.8               8               4.7     1.30 (0.57--2.95)
  Past use (31--365 days)            18                    0.9               0               0.0     --
  **DIPYRIDAMOLE**                                                                                   
  Non-use                            1920                  96.0              161             95.3    1 (--)
  Current use (0--30 days)           65                    3.2               8               4.7     1.38 (0.63--3.06)
  Past use (31--365 days)            15                    0.8               0               0       --
  **NITRATES**                                                                                       
  Non-use                            1321                  66.1              103             61.0    1 (--)
  Current use (0--30 days)           412                   20.6              36              21.30   0.93 (0.61--1.42)
  Past use (31--365 days)            267                   13.3              30              17.7    1.20 (0.76--1.90)

\**Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, NSAIDs, and PPIs*.

*Note: Data on PCP visits, number of referrals and number of hospitalizations were collected for the year prior to the index date. Data on comorbidity was collected for any time before the start date*.

*ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal anti-inflammatory drug; PCP, primary care practitioner; PPI, proton pump inhibitor; PU, peptic ulcer; RR, relative risk; UGIB, upper gastrointestinal bleeding*.

Current use of clopidogrel (with or without low-dose ASA) was associated with a significant increase in the risk of UGIB compared with non-use (RR, 1.90; 95% CI, 1.12--3.22). Current users of dual antiplatelet therapy (ASA and clopidogrel) had a significantly higher risk of UGIB than individuals using neither antiplatelet therapy (RR, 3.31; 95% CI, 1.18--9.24) and a non-significant increase in the risk of UGIB compared with those using low-dose ASA monotherapy (RR, 1.61; 95% CI, 0.85--3.05).

Recent discontinuers of low-dose ASA had a lower risk of UGIB compared with those who continued low-dose ASA therapy (RR, 0.71; 95% CI, 0.42--1.20; Table [3](#T3){ref-type="table"}). When we examined the risk of UGIB by the reason for discontinuation, individuals discontinuing ASA due to safety concerns had a RR of 2.18 (95% CI, 0.80--5.95) compared with current users, while discontinuation for other reasons (primarily non-adherence) was associated with an RR of 0.52 (95% CI, 0.28--0.99).

###### 

**The prevalence of low-dose ASA discontinuation in individuals with UGIB and controls with no UGIB, and its association with a diagnosis of UGIB, in a cohort of low-dose ASA users**.

                                                                Controls *N* = 2000   UGIB Cases *N* = 169   RR (95% CI)\*          
  ------------------------------------------------------------- --------------------- ---------------------- --------------- ------ -------------------
  **LOW-DOSE ASA STATUS**                                                                                                           
  Current users                                                 1494                  74.7                   131             77.5   1 (--)
  Recent discontinuers                                          263                   13.1                   19              11.2   0.71 (0.42--1.20)
  Past discontinuers                                            57                    2.9                    6               3.6    1.03 (0.40--2.62)
  **REASON FOR DISCONTINUATION (AMONG RECENT DISCONTINUERS)**                                                                       
  Not safety related^†^                                         244                   12.2                   12              7.1    0.52 (0.28--0.99)
  Safety related                                                19                    0.9                    7               4.1    2.18 (0.80--5.95)

\**Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, NSAIDs and PPIs*.

^†^*Includes discontinuation due to lack of efficacy, non-adherence or OTC ASA use*.

*Note: The remaining group not included in the table were all individuals who had non-use of ASA within the year prior to index date (186 controls and 13 cases) Data on PCP visits, number of referrals and number of hospitalizations were collected for the year prior to the index date. Data on comorbidity was collected for any time before the start date*.

*ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal anti-inflammatory drug; OTC, over-the-counter; PCP, primary care practitioner; PPI, proton pump inhibitor; PU, peptic ulcer; RR, incidence rate ratio; UGIB, upper gastrointestinal bleeding*.

Table [4](#T4){ref-type="table"} shows the RR of UGIB associated with various anti-inflammatory drugs. Compared with non-use, an increased risk of UGIB was found in current users of NSAIDs (RR, 2.66; 95% CI, 1.66--4.26). The increase in the risk of UGIB was higher in those who had been using NSAIDs for less than 31 days (RR, 3.49; 95% CI, 1.49--8.18) than in those who had been using longer than 30 days (RR, 2.19; 95% CI, 1.22--3.92) compared with non-users. No relationship was found between NSAID dose and the risk of UGIB. Concomitant users of ASA and NSAIDs had a RR of 5.90 (95% CI, 2.39--14.53) compared with individuals using neither ASA nor NSAIDs. There was no significant association between oral corticosteroid use and the risk of UGIB.

###### 

**Anti-inflammatory drug use in individuals with UGIB and controls with no UGIB, and its association with a diagnosis of UGIB, in a cohort of low-dose ASA users**.

                                 Controls *N* = 2000   UGIB Cases *N* = 169   RR (95% CI)\*          
  ------------------------------ --------------------- ---------------------- --------------- ------ --------------------
  **NSAIDs**                                                                                         
  Non-use                        1607                  80.3                   116             68.6   1 (--)
  Current use                    156                   7.8                    28              16.6   2.66 (1.66--4.26)
     Single NSAID                143                   7.1                    24              14.2   2.50 (1.52--4.11)
     Multiple NSAIDs             13                    0.7                    4               2.4    4.41 (1.33--14.63)
  Past use                       237                   11.8                   25              14.8   1.39 (0.86--2.26)
  **DURATION OF NSAID USE^†^**                                                                       
  ≤30 days                       33                    1.7                    8               4.7    3.49 (1.49--8.18)
  31--365 days                   64                    3.2                    9               5.3    2.07 (0.97--4.42)
  \>1 year                       46                    2.3                    7               4.1    2.35 (1.00--5.57)
  **NSAID DOSE^†^**                                                                                  
  Low--medium                    65                    3.2                    13              7.7    3.13 (1.61--6.06)
  High                           65                    3.2                    10              5.9    2.10 (1.01--4.34)
  Unknown                        13                    0.6                    1               0.6    1.49 (0.19--11.73)
  **INTERACTION WITH NSAIDs**                                                                        
  ASA without NSAID              1260                  63.0                   92              54.4   1 (--)
  ASA plus NSAID                 133                   6.7                    26              15.4   2.92 (1.77--4.82)
  **ORAL CORTICOSTEROIDS**                                                                           
  Non-use                        1891                  94.6                   159             94.1   1 (--)
  Current use (0--30 days)       60                    3.0                    5               3.0    0.88 (0.33--2.31)
  Past use (31--365 days)        49                    2.4                    5               3.0    0.97 (0.36--2.62)

\**Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, NSAIDs, and PPIs*.

^†^*Duration and dose--response was evaluated among current single NSAID users. Reference group for duration and dose--response was non-use. Specific cut-off values for dose (in mg) were as follows: aceclofenac 200, acemetacin 120, azapropazone 600, celecoxib 200, diclofenac 100, diflunisal 1500, etodolac 400, etoricoxib 90, fenbufen 900, fenoprofen 1200, flurbiprofen 150, ibuprofen 1200, indomethacin 75, ketoprofen 150, ketorolac 30, mefenamic acid 1000, meloxicam 7.5, nabumetone 1000, naproxen 750, piroxicam 10, rofecoxib 25, sulindac 200, tenoxicam 10, tiaprofenic 600, and valdecoxib 20. Doses less than or equal to the cut-off value were grouped under low--medium doses, and doses greater than the cut-off value were grouped under high doses*.

*Note: Data on PCP visits, number of referrals and number of hospitalizations were collected for the year prior to the index date. Data on comorbidity was collected for any time before the start date*.

*ASA, acetylsalicylic acid; CI, confidence interval; NSAID, non-steroidal anti-inflammatory drug; OTC, over-the-counter; PCP, primary care practitioner; PPI, proton pump inhibitor; PU, peptic ulcer; RR, relative risk; UGIB, upper gastrointestinal bleeding*.

Table [5](#T5){ref-type="table"} presents the RR of UGIB associated with acid-suppressing drugs. Current PPI users who initiated this treatment at or before the start date had a significantly reduced risk of UGIB compared with non-users (RR, 0.56; 95% CI, 0.33--0.96). Current PPI users who initiated this therapy after the start date had an increased risk of UGIB, presumably due to confounding by indication. The reduced risk of UGIB was found among current PPI users who were receiving a medium or high daily dose (RR, 0.40; 95% CI, 0.20--0.78), but was not observed among users of a low daily dose (RR, 1.00; 95% CI, 0.47--2.12). No significant association was found between H~2~RA use and the risk of UGIB (RR, 1.07; 95% CI, 0.47--2.42).

###### 

**PPI and H~2~RA use in individuals with UGIB and controls with no UGIB, and its association with a diagnosis of UGIB, in a cohort of low-dose ASA users**.

                                                              Controls *N* = 2000   Cases *N* = 169   RR (95% CI)\*   N = 2000   N = 169
  ----------------------------------------------------------- --------------------- ----------------- --------------- ---------- -------------------
  **PPI USE AT INDEX DATE**                                                                                                      
  Non-use                                                     1490                  74.5              107             63.3       1 (--)
  Current use (0--30 days)                                    400                   20.0              46              27.2       0.97 (0.65--1.44)
  Past use (31--365 days)                                     110                   5.5               16              9.5        1.30 (0.70--2.41)
  **PPI USE AT START DATE**                                                                                                      
  Non-use                                                     1490                  74.5              107             63.3       1 (--)
  Current users initiating PPI therapy after start date       135                   6.8               25              14.8       1.88 (1.14--3.13)
  Current PPI users initiating PPI at start date              265                   13.2              21              12.4       0.56 (0.33--0.96)
     Low PPI dose^†^                                          84                    4.2               9               5.3        1.00 (0.47--2.12)
     Medium/high PPI dose^†^                                  181                   9.0               12              7.1        0.40 (0.20--0.78)
  **H~2~RA AT INDEX DATE**                                                                                                       
  Non-use                                                     1885                  94.2              152             89.9       1 (--)
  Current use (0--30 days)                                    84                    4.2               12              7.1        1.08 (0.55--2.11)
  Past use (31--365 days)                                     31                    1.6               5               3.0        1.45 (0.51--4.12)
  **H~2~RA AT START DATE**                                                                                                       
  Non-use                                                     1885                  94.2              152             89.9       1 (--)
  Current users initiating H~2~ RAtherapy after start date    28                    1.4               4               2.4        1.09 (0.36--3.31)
  Current PPI users initiating H~2~RA therapy at start date   56                    2.8               8               4.7        1.07 (0.47--2.41)

\**Adjusted by sex, age, follow-up time, history of peptic ulcer disease, number of PCP visits, referrals and hospitalizations, and use of warfarin, ASA, clopidogrel, NSAIDs and PPIs*.

^†^*Specific cut-off values for daily dose (in mg) were as follows: esomeprazole 10, lansoprazole 15, omeprazole 10, rabeprazole 10, pantoprazole 10 mg. Doses less than or equal to the cut-off value were grouped under low doses, and doses greater than the cut-off value were grouped under medium/high doses*.

*ASA, acetylsalicylic acid; CI, confidence interval; H~2~RA, histamine-2 receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; PCP, primary care practitioner; PPI, proton pump inhibitor; PU, peptic ulcer; RR, relative risk; UGIB, upper gastrointestinal bleeding*.

Discussion
==========

The incidence of UGIB in this cohort of low-dose ASA users was 1.12 per 1000 person-years. The incidence of UGIB was increased more than fivefold in those with a history of peptic ulcer disease, confirming the results of other studies that have shown this to be the strongest risk factor for UGIB (Hernández-Díaz and García Rodríguez, [@B12]; Lanas et al., [@B18]).

Current use of 75 mg ASA was associated with a 50% increase in RR and use of 150--300 mg ASA with a greater than two-fold increase in the risk of UGIB compared with non-use, which is consistent with the results of previous clinical trials and observational studies (Weil et al., [@B28]; Kelly et al., [@B14]; de Abajo and García Rodríguez, [@B5]; García Rodríguez et al., [@B9]). Our study also shows that discontinuation of low-dose ASA therapy was associated with a 30% reduction in the risk of UGIB compared with continuation of therapy, suggesting that the gastric mucosa reverts to its pre-treatment stage after treatment is withdrawn. When we stratified this analysis by the reason for low-dose ASA discontinuation, the reduced risk of UGIB was found among those who discontinued ASA for reasons unrelated to safety whereas a marked increase in the risk of UGIB was found among those who discontinued low-dose ASA for safety reasons. This strongly suggests a confounding by indication (reason for discontinuation) in this latter subgroup of discontinuers.

Adding to the literature on the beneficial effects of PPIs in this patient group (Lanas et al., [@B16], [@B18]), we also found that concomitant PPI use reduces the risk of UGIB in low-dose ASA users by almost 50%. The beneficial effect of PPIs was only found if they were initiated at the same time as the low-dose ASA or before the first low-dose ASA prescription. Again this suggests a confounding by indication for PPI use in those who were not prescribed a PPI until sometime after their low-dose ASA prescription. Our data on use of H2RAs was limited and we could not assess with precision the effect of this drug class. Some studies have shown a protective effect of H2RAs on the risk of UGIB among ASA users (Lanas et al., [@B17]).

We also found that prescribing ASA together with other drugs, such as NSAIDs or clopidogrel, confers an increased risk of UGIB. Users of clopidogrel had an almost twofold increase in the risk of UGIB compared with non-users, which supports the results of other case--control studies (Hallas et al., [@B10]; Ibáñez et al., [@B13]). The inhibition of platelet aggregation by clopidogrel, in addition to causing a vascular homeostatic imbalance, could have a role in ulcer healing (Ma et al., [@B21]; Lanas and Scheiman, [@B19]), leading to a relapse of latent ulcers.

NSAID use was also associated with an increase in the risk of UGIB in users of low-dose ASA, but this increase was smaller than that found in studies of the general population (Hernández-Díaz and García Rodríguez, [@B11]). This was probably due to our cohort being restricted to individuals taking low-dose ASA for secondary prevention of cardiovascular events. These individuals already have complete inhibition of thromboxane-mediated platelet aggregation afforded by aspirin, which means that the increase in the risk of UGIB in these individuals due to concomitant use of low-dose ASA and NSAIDs is most likely a result of directly induced gastrointestinal ulceration.

Our study has several strengths and limitations. A key strength is that the records of potential cases (including free-text comments) were manually reviewed. In a previous study, this method of case ascertainment was shown to have a positive predictive value of almost 95% when PCPs were contacted in order to confirm the diagnosis (García Rodríguez and Barreales Tolosa, [@B7]). In addition, although our study is retrospective, data were recorded prospectively by the PCP before the episode of interest. We tried to minimize any residual confounding; however, some level of misclassification is unavoidable in a database of this size. However, non-differential misclassification should have biased our estimates of effect toward the null and does not explain the strong associations and dose--response relationships observed in our study. Also, the lack of systematic recording of over-the-counter ASA is another source of misclassification, however it should be noted that individuals aged over 60 years (the majority of our study members) are eligible for free prescriptions, which indicates a high likelihood to collect the prescription. Despite the large size of the total study cohort, the number of UGIB cases was small, which may have affected the results of some of the sub-analyses as the study of dose and duration--response according to ASA use. Another limitation is the lack of consistent recording of *H. pylori* infection in THIN, which made it impossible to isolate the effect of *H. pylori* and *H. pylori*eradication on the risk of UGIB.

In conclusion, the results of the present study provide additional evidence that a history of peptic ulcer disease increases the risk of UGIB among new users of low-dose ASA for secondary prevention of cardiovascular and cerebrovascular events. In addition, these data support the finding that combining ASA with NSAIDs or clopidogrel increases further the risk of UGIB; while prescribing a PPI when initiating low-dose ASA therapy reduces the risk of UGIB.

Discontinuation of low-dose ASA also reduces the risk of UGIB. However, individuals with a history of cardiovascular events who discontinue treatment with low-dose ASA are known to be at increased risk of myocardial infarction (García Rodríguez et al., [@B8]), transient ischemic attack (Maulaz et al., [@B22]) and death (Collet et al., [@B4]) compared with those who continue treatment. When prescribing low-dose ASA to individuals at high gastrointestinal risk, clinicians should therefore weigh the potential benefit of co-prescribing a PPI to reduce the burden of gastrointestinal disease in these patients.
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